Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy.

Publikation

Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy.

Wissenschaftlicher Artikel/Review - 04.05.2023

Chatziioannou Eftychia, Leiter Ulrike, Thomas Ioannis, Keim Ulrike, Seeber Olivia, Meiwes Andreas, Boessenecker Isabell, Gonzalez Stephanie Sanchez, Torres Francisco Merraz, Niessner Heike, Sinnberg Tobias, Forschner Andrea, Flatz Lukas, Amaral Teresa

Zitation

Chatziioannou E, Leiter U, Thomas I, Keim U, Seeber O, Meiwes A, Boessenecker I, Gonzalez S, Torres F, Niessner H, Sinnberg T, Forschner A, Flatz L, Amaral T. Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy. Am J Clin Dermatol 2023; 24:453-467.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Am J Clin Dermatol 2023; 24

Veröffentlichungsdatum

04.05.2023

eISSN (Online)

1179-1888

Seiten

453-467

Kurzbeschreibung/Zielsetzung

Immune checkpoint inhibition (ICI) has changed the melanoma treatment spectrum. Few studies have examined the characteristics and long-term outcomes of patients achieving complete response (CR) under ICI.